Cargando…

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance

The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based targeted therapy remains the main driving force to identify novel molecular targets that are capable to increase GISTs sensitivity to the current therapeutic regimens. Secondary resistance to IM in G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boichuk, Sergei, Galembikova, Aigul, Dunaev, Pavel, Valeeva, Elena, Shagimardanova, Elena, Gusev, Oleg, Khaiboullina, Svetlana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149963/ https://www.ncbi.nlm.nih.gov/pubmed/29206199 http://dx.doi.org/10.3390/molecules22122152

Ejemplares similares

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
por: Boichuk, Sergei, et al.
Publicado: (2018)

Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair
por: Boichuk, Sergei, et al.
Publicado: (2020)

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline
por: Boichuk, Sergei, et al.
Publicado: (2023)

Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors
por: Sergei, Boichuk, et al.
Publicado: (2020)

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines
por: Boichuk, Sergei, et al.
Publicado: (2021)

Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib
por: Boichuk, Sergei, et al.
Publicado: (2020)

The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site
por: Boichuk, Sergei, et al.
Publicado: (2021)

Computational-Based Discovery of the Anti-Cancer Activities of Pyrrole-Based Compounds Targeting the Colchicine-Binding Site of Tubulin
por: Boichuk, Sergei, et al.
Publicado: (2022)

Microbiota composition data of imago and larval stage of the anhydrobiotic midge
por: Shaikhutdinov, Nurislam, et al.
Publicado: (2020)

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors
por: Tomasetti, Cristian, et al.
Publicado: (2013)

Downsizing Treatment with Tyrosine Kinase Inhibitors in Patients with Advanced Gastrointestinal Stromal Tumors Improved Resectability
por: Sjölund, Katarina, et al.
Publicado: (2010)

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors
por: Li, Jian, et al.
Publicado: (2018)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review
por: Feng, Mingyang, et al.
Publicado: (2022)

Diversity and Regulation of S-Adenosylmethionine Dependent Methyltransferases in the Anhydrobiotic Midge
por: Deviatiiarov, Ruslan, et al.
Publicado: (2020)

DetR DB: A Database of Ionizing Radiation Resistance Determinants
por: Ryabova, Alina, et al.
Publicado: (2020)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors
por: Na, Young-Soon, et al.
Publicado: (2017)

Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy
por: Qiu, Hai-Bo, et al.
Publicado: (2018)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes
por: Yong, Zachary Zihui, et al.
Publicado: (2021)

Cerebellar Atrophy and Changes in Cytokines Associated with the CACNA1A R583Q Mutation in a Russian Familial Hemiplegic Migraine Type 1 Family
por: Khaiboullina, Svetlana F., et al.
Publicado: (2017)

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
por: van de Wal, Deborah, et al.
Publicado: (2022)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Combined metabolome and transcriptome analysis reveals key components of complete desiccation tolerance in an anhydrobiotic insect
por: Ryabova, Alina, et al.
Publicado: (2020)

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors
por: Wang, Feng, et al.
Publicado: (2021)

Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
por: Van Looy, Thomas, et al.
Publicado: (2014)

Application of Multigene Panels Testing for Hereditary Cancer Syndromes
por: Bilyalov, Airat, et al.
Publicado: (2022)

Receptor Tyrosine Kinases: Molecular Switches Regulating CNS Axon Regeneration
por: Vigneswara, Vasanthy, et al.
Publicado: (2012)

Identification of a master transcription factor and a regulatory mechanism for desiccation tolerance in the anhydrobiotic cell line Pv11
por: Yamada, Takahiro G., et al.
Publicado: (2020)

Unraveling the Mechanism of Platelet Aggregation Suppression by Monoterpenoids
por: Nikitina, Liliya E., et al.
Publicado: (2022)

Phosphorylation of tyrosine 90 in SH3 domain is a new regulatory switch controlling Src kinase
por: Koudelková, Lenka, et al.
Publicado: (2023)

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials
por: Wu, Lile, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aqncnpre2tm40feh37ol2ole23